Our Technology Partn3Ring webinar series showcases technologies with 3Rs potential to the wider scientific community to identify new partners for further development, qualification and use. Webinars consist of short pitches outlining the 3Rs technologies and unique opportunities for collaboration.
Upcoming webinar
Details of our next event will be made available on this page and announced in the NC3Rs newsletter. All webinars are open to researchers, clinicians, pharmaceutical and industry professionals. Audience members will be able to ask questions to the speakers and learn about how to get involved with each opportunity have the opportunity to connect with the speakers to access the showcased technologies.
Have an opportunity to present?
Apply to present if your technology, tool or service has the potential to deliver 3Rs benefits and:
You are seeking collaborators to support the further development required to achieve this and maximise the scientific, commercial and animal welfare benefits of your approach.
or
- You are seeking users of your technology to realise the 3Rs impacts of your approach.
Presentations are welcome from researchers and technology developers from across the life science sector, including academia and SMEs.
Showcased technologies
The recorded pitches from previous webinars are available below. They are uploaded within one week of the session and will be accessible for 12 months.
Oncology Technology Partn3Ring: Wednesday 24 September 2025
Speakers:
- Patient-derived organoid model for oncology drug testing.
Dr Chloé Prunier (INOVOTION). - Drosophila screening service for therapeutics.
Dr Nicole Dawney (RxCelerate). - ATMS Dynamic Culture platform.
Dr Vanessa Zaiatz Bittencourt (Taihoya). - 3D bioprinted bone marrow-leukaemia co-culture organoids.
Dr Deepali Pal (University of Bristol). - Animal free peptide hydrogel for 3D cell culture.
Dr Viola Erdelyi (Peptimatrix). - Chorioallantoic membrane (CAM) assay.
Professor Judy M Coulson (University of Liverpool).
Researchers can also engage with our Oncology Network that supports scientists from across sectors to establish collaborations and catalyses the uptake of 3Rs technologies.
Dr Chloé Prunier, INOVOTION
Pitch title: Patient-derived organoid model for oncology drug testing: The chicken embryo model.
Collaboration opportunity: Inovotion are seeking collaborations with hospitals, research institutions, and biotech companies working with organoids or patient-derived cancer models. The aim is to co-develop and validate applications of their organoid-on-CAM platform using clinical samples and therapeutic candidates.
Dr Nicole Dawney, RxCelerate
Pitch title: Tiny flies, big impact: Why Drosophila belong in drug discovery.
Collaboration opportunity: RxCelerate Ltd are looking to raise awareness of how Drosophila can support drug discovery and tailor approaches to each client’s goals. They invite researchers interested in these models to get in touch to discuss their needs.
Dr Vanessa Zaiatz Bittencourt, Taihoya
Pitch title: ATMS - Precision Mechanobiology to transform in vitro oncology research
Collaboration opportunity: Taihoya are looking for collaborators with expertise in disease modeling, biomaterials, or drug testing. Ideally, partners can provide complementary technologies, access to relevant cell types or models, and/or support for comparative studies against animal-based methods.
Dr Deepali Pal, University of Bristol
Pitch title: 3D bioprinted bone marrow-leukaemia co-culture organoids.
Collaboration opportunity: They are looking to partner with pharmaceutical and biotech companies needing in vitro tools, including animal-free synthetic biomimetic culture matrices, for target discovery and screening. They also welcome collaborations with groups willing to share inhibitor libraries or compounds.
Dr Viola Erdelyi, Peptimatrix
Pitch title: Animal free peptide hydrogel for 3D cell culture.
Collaboration opportunity: PeptiMatrix are looking for collaborators to test their gel with different cancer cell lines or organoid models, and to explore applications such as spheroid growth of cancer cells or related research areas.
Professor Judy Coulson, University of Liverpool
Pitch title: Using fertilised hens' eggs to replace mammalian models in oncology research and therapeutic testing.
Collaboration opportunity: They are seeking clinical contacts to expand collaboration on PDX models and pre-clinical studies, as well as partners with regulatory or industry expertise to support model qualification and wider acceptance. They also welcome complementary expertise, resources, or validation capabilities.
Cardiovascular Technology Partn3Ring: Thursday 27 February 2025
Speakers:
- Signal processing method (SPAR).
Professor Manasi Nandi (King’s College London). - Multicellular organ-on-a-chip model.
Professor Beata Wojciak-Stothard (Imperial College London). - Functional human heart tissue (native and engineered) models.
Professor Helen Maddock (InoCardia).
Researchers can also engage with our Cardiovascular Network that supports scientists from across sectors to establish collaborations and catalyses the uptake of 3Rs technologies.
Professor Manasi Nandi, Kings College London
Pitch title: Adding a new dimension to vital sign data to detect drug, gene or disease effects: SPAR.
Collaboration opportunity: Any academic or industry scientists who collect continuous continuous cyclic data. Typically those sampling cardiovascular or respiratory waveforms to understand the effects of gene/drug/model intervention on cardiovascular and respiratory physiology.
Professor Helen Maddock, InoCardia
Pitch title: Functional human heart tissue (native & engineered) model.
Collaboration opportunity: Pharmaceutical companies, CROs, Stem Cell companies/developers and academics interested in collaboration or partnering.
Professor Beata Wojciak-Stothard, Imperial College London
Pitch title: Capturing complexity: organ-on-a-chip models of vascular dysfunction in lung disease.
Collaboration opportunity: Input from the Pharmaceutical industry on how to optimise the model and what measurable outputs are important for its further development. The team would like to test the system for drug screening and toxicology studies.